<DOC>
	<DOCNO>NCT00285233</DOCNO>
	<brief_summary>The objective study assess safety efficacy islet allotransplantation reestablishment stable glycemic control patient type 1 diabetes , use anti-thymocyte globulin induction immunosuppression sirolimus , mycophenolate mofetil low dose tacrolimus maintenance immunosuppression .</brief_summary>
	<brief_title>Delayed Mycophenolate Mofetil Single-Donor Islet Allotransplantation Type 1 Diabetes</brief_title>
	<detailed_description>To assess safety efficacy new single-donor islet allotransplant protocol focus minimization ischemic damage two-layer pancreas preservation technique , attenuation posttransplant nonspecific inflammatory response etanercept anti-thymocyte globulin , deletion/inactivation autoreactive T cell anti-thymocyte globulin daclizumab induction immunotherapy , potent yet non-diabetogenic maintenance immunosuppression sirolimus delayed mycophenolate mofetil instead tacrolimus reestablishment stable glycemic control recipient type 1 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Primary islet allotransplant 2 . Type 1 diabetes mellitus , complicate least one follow situation persist despite intensive effort close cooperation diabetes care team : 1 . Metabolic lability/instability ; 2 . Reduced awareness hypoglycemia ; 3 . Persistently poor glucose control ( define HgbA1c &gt; 10 % end six month intensive management effort diabetes care team ) ; 4 . Progressive secondary complication . 3 . Age 18 old 4 . Able give write informed consent 1 . Known hypersensitivity rabbit protein . 2 . Presence history panelreactive antiHLA antibody ( &gt; 10 % ) . 3 . Insufficient cardiovascular reserve . 4 . Creatinine clearance &lt; 60 mL/min/m2 . 5 . Portal hypertension , abnormal liver enzyme test , history significant liver disease . 6 . History malignancy within 5 year . 7 . Active peptic ulcer disease . 8 . Severe unremitting diarrhea gastrointestinal disorder potentially interfere ability absorb oral medication . 9 . Pregnancy breastfeed . 10 . Active infection . 11 . Serological evidence infection HIV , HBsAg HCVAb positive within previous 12 month prior transplantation . 12 . Negative screen EpsteinBarr Virus ( EBV ) EBNA method 13 . Evidence infiltrate , cavitation , consolidation chest xray prestudy screen . 14 . Schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication . 15 . Ongoing substance abuse ; drug alcohol . 16 . Recent history noncompliance . 17 . Any medical condition , opinion investigator , interfere safe completion trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>